IPJ

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office

Retrieved on: 
Thursday, February 15, 2024

This is to amend Article 1 (Corporate Name) and Article 3 (Head Office) of the current Articles of Incorporation to make the change of corporate name of the Company mentioned in 1 and the change of the location of the Company mentioned in 2 above.

Key Points: 
  • This is to amend Article 1 (Corporate Name) and Article 3 (Head Office) of the current Articles of Incorporation to make the change of corporate name of the Company mentioned in 1 and the change of the location of the Company mentioned in 2 above.
  • The name of the Company shall be “Sosei Group Kabushiki Kaisha,” and shall be “Sosei Group Corporation” in English.
  • The Head Office of the Company shall be located in Chiyoda-ku, Tokyo, Japan.
  • The name of the Company shall be “Nxera Pharma Kabushiki Kaisha,” and shall be “Nxera Pharma Co., Ltd.” in English.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer

Retrieved on: 
Friday, January 5, 2024

Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer (“COO”).

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer (“COO”).
  • Mr. Maeda brings with him a breadth of global management and commercialization experience and a strong background rooted in the pharmaceutical industry.
  • He also worked at McKinsey and Company in Japan and the UK where he gained global business experience in healthcare industry.
  • Chris Cargill, CEO and President of Sosei Heptares, commented: “I’m delighted to welcome Toshihiro to the team here at Sosei Heptares.

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

Retrieved on: 
Thursday, December 7, 2023

Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.

Key Points: 
  • Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
  • The MFDS approval is based on scientific and clinical data from an extensive Japanese Phase 3 program submitted by Idorsia Pharmaceuticals Korea (“IPK”), a Sosei Group company.
  • In South Korea, the Marketing Authorization of PIVLAZ™ is held by IPK and will become commercially available to patients in early 2025.
  • PIVLAZ™ received marketing approval in Japan in January 2022 and was launched in April 2022 by Idorsia Pharmaceuticals Japan ("IPJ”), also a Sosei Group company.

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Retrieved on: 
Friday, November 10, 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.
  • Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic expansion.
  • Note regarding the Idorsia transaction: the quarter ended 30 September 2023 (Q3 2023) is the first period in which the Group has consolidated the financial results of Idorsia’s former Japanese and South Korean businesses.
  • Revenue totalled JPY 5,474 million (US$39.6 million*), a decrease of JPY 3,167 million (US$27.9 million) vs. the prior corresponding period.

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Thursday, July 20, 2023

This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.

Key Points: 
  • This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.
  • “The Japan pharmaceutical market, given its size, large ageing population and attractive high quality clinical development and regulatory environment is the key next step for Sosei Heptares’ growth ambitions.
  • I would also like to welcome Dr. Satoshi Tanaka and the other members of the IPJ and IPK teams to Sosei Heptares.
  • The acquisition of IPJ and IPK addresses this objective and is the conclusion of a rigorous global search by the Sosei Heptares team.

SiTime Expands Portfolio of Precision Timing Solutions for Aerospace and Defense with Two New Endura Oscillator Families

Retrieved on: 
Thursday, January 26, 2023

SiTime Corporation , (Nasdaq: SITM), the precision timing company, today announced two new Endura™ precision timing oscillator families.

Key Points: 
  • SiTime Corporation , (Nasdaq: SITM), the precision timing company, today announced two new Endura™ precision timing oscillator families.
  • In addition, the Endura Super-TCXO family delivers up to 5x better stability, while the differential oscillator family delivers the best jitter.
  • “Timing technology is ever more crucial in aerospace and defense applications where extreme conditions are the norm,” said Fari Assaderaghi, EVP, Technology and Engineering, SiTime.
  • Upon release, all Endura precision timing solutions will be available on SiTimeDirect ™ for quick configuration and 48-hour shipments.